Table 5—

Assessment of asthma control improvement(change in Asthma Control Questionnaire (ΔACQ) <-0.5)

Nonsmokers#Smokers#
TotalD ≤500D >500ACQ <2+ΔD 0§TotalD ≤500D >500ACQ <2+ΔD 0§
Total events n6433063374323019235575347
Positive cases n2571161411121084014261815
Prevalence40384226364341463432
Sensitivity64745560535762505667
Specificity71677470667484717775
PPV61586041476275595657
NPV74807083727078637783
Accuracy68706666656677617072
p-valueƒ<0.001<0.001<0.001<0.0010.002<0.001<0.0010.070<0.001<0.001
  • Data are presented as %, unless otherwise indicated. PPV: positive predictive value; NPV: negative predictive value. #: cut-off value of -20%; : inhaled corticosteroid (ICS) dose (D) in μg equivalents of beclomethasone diproprionate·day−1; +: ACQ <2 tested the subgroup with an initial ACQ score of <2; §: ΔD 0 tested the subgroup without treatment modification between consecutive visits; ƒ: the p-value was defined as the statistical significance of rejecting an area under the curve of 0.5. A positive event was defined as an improvement in asthma control. A true-positive case was defined as an exhaled nitric oxide fraction (FeNO) change of less than or the same as a cut-off value (e.g. -25%) associated with an improvement of asthma control between consecutive visits. When smoking patients were treated with a high ICS dose, FeNO lost its ability to assess a control improvement (p = 0.07).